INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said that more than
two-thirds of people with atopic dermatitis and skin of color experienced skin
improvement in a first-of-its-kind lebrikizumab study.

The company stated that the lebrikizumab efficacy results from the trial are
consistent with data in other Phase 3 studies, which further reinforces
lebrikizumab's potential to be a first-line biologic treatment following topical
prescription therapies for people across a range of skin tones with
moderate-to-severe atopic dermatitis.

According to the company, the initial 16-week data from this study evaluated 50
patients with moderate-to-severe atopic dermatitis and darker skin tones as
measured by the Fitzpatrick scale¶, including people who self-identify as Black
or African American (80%), Asian (14%), American Indian or Alaska Native (6%).
Of the 50 patients, 11 also self-identified as Hispanic/Latinx (22%) with the
remaining 39 self-identifying as non-Hispanic/Latinx (78%). All patients
received lebrikizumab 500-mg subcutaneously initially and at two weeks followed
by 250-mg subcutaneously every two weeks to Week 16. Results at 16 weeks were
consistent with the 16-week results from the ADhere and ADvocate 1 & 2 studies.

No new safety signals were observed and there were no serious adverse events
reported. The study also included a physician assessment of changes in
post-inflammatory pigmentation using the newly developed PDCA-Derm scale. Full
efficacy and safety results from the study will be shared at future congresses.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX